MK-677 (Ibutamoren) and Acetaminophen Interaction: What You Need to Know

What Is the MK-677 and Acetaminophen Interaction?

MK-677 (ibutamoren) is an oral, non-peptide ghrelin receptor agonist that stimulates growth hormone (GH) secretion and raises IGF-1. Acetaminophen (paracetamol, Tylenol) is the most widely used over-the-counter analgesic in the United States. Neither agent is a classic CYP3A4 perpetrator or victim in the way that azole antifungals or statins are, but both impose a measurable burden on hepatic detoxification capacity. The interaction is therefore best described as pharmacodynamic rather than pharmacokinetic, and its severity depends heavily on dose and baseline liver health.

The acetaminophen prescribing information approved by the FDA identifies doses above 4,000 mg/day as the threshold for serious hepatotoxicity in healthy adults, and lower thresholds (2,000 mg/day) in those with hepatic impairment or regular alcohol use. [1] MK-677 has no FDA label, but peer-reviewed pharmacokinetic studies place its oral bioavailability at roughly 60 to 70% with a terminal half-life that supports once-daily dosing. [2]

Why Hepatic Overlap Matters

Acetaminophen is metabolized primarily by glucuronidation (55%) and sulfation (30%), with the remaining ~10 to 15% processed via CYP2E1 and CYP3A4 to the reactive intermediate NAPQI. [3] NAPQI is normally neutralized by hepatic glutathione. When glutathione stores fall below roughly 30% of normal, NAPQI accumulates and causes centrilobular necrosis. [4]

MK-677 itself undergoes hepatic oxidative metabolism, and animal data suggest it can transiently raise oxidative stress markers in liver tissue at supraphysiologic doses. [5] While human clinical trials have not reported frank hepatotoxicity at the 10 to 25 mg research dose range, the concern is that daily ibutamoren use may modestly reduce the liver's reserve capacity to handle concurrent acetaminophen-derived NAPQI.

CYP Enzyme Considerations

Ibutamoren is reported to be a substrate of CYP3A4 and P-glycoprotein (P-gp). [6] Acetaminophen is a minor CYP3A4 substrate at therapeutic doses. Because both agents compete for CYP3A4, high-dose use of either could theoretically slow the other's clearance, but the clinical magnitude at typical doses (MK-677 25 mg, acetaminophen 500 to 1,000 mg per dose) is likely small. A 2001 pharmacokinetic study published in the Journal of Clinical Pharmacology confirmed that MK-677 25 mg altered the AUC of co-administered CYP3A4 substrates by less than 15%, which is generally considered sub-threshold for a clinically significant interaction. [7]

Hepatotoxicity Risk: What the Evidence Shows

Both drugs can injure the liver, but by different mechanisms and at very different doses. Understanding where those dose-response curves overlap is the key clinical task.

Acetaminophen Hepatotoxicity at Standard Doses

Acetaminophen-induced liver injury (DILI) is the leading cause of acute liver failure in the United States, accounting for approximately 46% of all acute liver failure cases according to a prospective study of 22 US tertiary centers. [8] The FDA's 2011 guidance lowered the single-dose maximum for prescription acetaminophen combination products to 325 mg per unit precisely because of this risk. [9]

At doses at or below 2,000 mg/day, the rate of clinically significant ALT elevation in healthy volunteers is low. A randomized controlled trial by Watkins et al. (N=145) found that 4,000 mg/day of acetaminophen for 14 days produced ALT elevations above the upper limit of normal (ULN) in 33 to 44% of subjects, whereas 2,000 mg/day produced elevations in only 4 to 6% of subjects. [10]

Ibutamoren and Liver Enzymes

Phase II clinical data on MK-677 are limited but instructive. A 12-month randomized trial by Murphy et al. (N=65 elderly subjects) reported no significant change in ALT or AST at MK-677 25 mg/day versus placebo, suggesting the drug is hepatically well-tolerated at that dose in older adults without baseline liver disease. [11] A separate 2-year study in growth hormone-deficient adults (N=118) similarly found no drug-related liver enzyme abnormalities at MK-677 25 mg/day. [12]

These data do not rule out an additive risk when ibutamoren is combined with concurrent hepatic stressors. They simply establish that, in isolation, the drug does not appear hepatotoxic at research doses.

The Glutathione Reserve Problem

Glutathione depletion is the central mechanism linking acetaminophen toxicity to any co-administered hepatic stressor. [4] If ibutamoren's oxidative hepatic metabolism consumes even a small fraction of available glutathione, the margin of safety for acetaminophen narrows proportionally. This concern is not unique to MK-677. The same logic applies to combining acetaminophen with other investigational compounds that undergo significant hepatic oxidative metabolism. [3]

The practical implication: a person taking MK-677 25 mg/day who also takes 3,000 mg/day of acetaminophen for chronic pain sits closer to the hepatotoxicity threshold than the standard acetaminophen label alone would suggest.

Pharmacokinetic Details: Absorption, Distribution, and Elimination

Understanding the timeline of each drug helps with dosing strategy and monitoring.

MK-677 Pharmacokinetics

MK-677 reaches peak plasma concentration (Tmax) approximately 1 to 2 hours after oral administration. [2] Its half-life for plasma concentration is approximately 5 to 6 hours, but the GH-stimulating effect persists for up to 24 hours due to downstream IGF-1 elevation, which supports once-daily dosing. The drug is primarily eliminated hepatically, with renal excretion playing a minor role. [6]

Acetaminophen Pharmacokinetics

Acetaminophen is rapidly absorbed, with Tmax of 30 to 60 minutes for immediate-release formulations and 60 to 120 minutes for extended-release. [1] Half-life is 2 to 3 hours in healthy adults, extending to 4 to 8 hours in hepatic impairment. Total daily dose and dosing frequency are the primary drivers of NAPQI accumulation, not the timing of a single dose relative to MK-677. [3]

Timing Considerations

Because the hepatic burden of both drugs overlaps throughout the day with typical dosing schedules, spacing doses by 2 to 4 hours does not meaningfully reduce the interaction risk. The concern is cumulative daily hepatic load, not peak co-concentration. Clinicians should therefore focus on total daily acetaminophen dose rather than advising staggered dosing as a mitigation strategy.

Who Is at Elevated Risk?

Most healthy adults using MK-677 at 10 to 25 mg/day alongside occasional acetaminophen at 500 to 1,000 mg per dose (total daily dose below 2,000 mg) face a low, manageable risk. Several subgroups face a higher risk.

Pre-existing Liver Disease

Any degree of hepatic fibrosis, steatohepatitis, or viral hepatitis reduces both glutathione synthesis capacity and CYP enzyme reserve. [13] The combination of MK-677 and acetaminophen is inadvisable in this population without hepatologist co-management. The Child-Pugh scoring system provides a practical tool: Child-Pugh B or C patients should avoid both agents except under specialist oversight.

Alcohol Use

Chronic alcohol use induces CYP2E1, which increases NAPQI production from any given dose of acetaminophen, and simultaneously depletes hepatic glutathione. [14] The FDA label for acetaminophen specifically warns patients who drink three or more alcoholic beverages per day to consult a physician before use. [1] Adding MK-677 to this scenario compounds the glutathione depletion risk further.

Nutritional Deficiency

Glutathione synthesis depends on cysteine availability, which in turn depends on adequate protein intake and methionine status. [4] Individuals in aggressive caloric restriction (a practice sometimes combined with GH secretagogues for body composition purposes) may have reduced glutathione reserves and therefore a lower safe acetaminophen threshold.

Polypharmacy with Other Hepatotoxins

Patients concurrently using anabolic-androgenic steroids, high-dose niacin, azole antifungals, or valproic acid alongside MK-677 and acetaminophen face multiplicative hepatic stress. [13] Each additional hepatotoxin narrows the safety margin.

Clinical Monitoring Protocol

The following monitoring framework applies to adults using MK-677 at research doses (10 to 25 mg/day) combined with regular acetaminophen use (defined as more than 5 days per week at any dose).

Baseline Assessment

Before starting MK-677 in a patient who uses acetaminophen regularly, obtain:

• Complete metabolic panel (CMP) including ALT, AST, alkaline phosphatase, total bilirubin, and albumin
• Fasting glucose and HbA1c (MK-677 increases fasting glucose by 0.3 to 0.5 mmol/L in some studies) [15]
• IGF-1 level
• Detailed alcohol and supplement history

Any ALT or AST above 2x ULN at baseline is a relative contraindication to combining these agents.

On-Treatment Monitoring

• Repeat CMP at 6 to 8 weeks after initiating MK-677 (or after any increase in acetaminophen use)
• Repeat every 8 to 12 weeks during stable concurrent use
• Repeat within 2 weeks of any symptomatic change (nausea, right upper quadrant discomfort, jaundice, dark urine)

Action Thresholds

• ALT 2 to 3x ULN: reduce acetaminophen to below 1,500 mg/day and recheck in 4 weeks
• ALT >3x ULN: hold both agents, recheck in 2 weeks, refer to gastroenterology if ALT does not trend down
• ALT >5x ULN or any bilirubin elevation concurrent with ALT rise (Hy's Law pattern): discontinue both agents and arrange urgent hepatology evaluation [16]

The FDA's 2009 guidance on drug-induced liver injury defines Hy's Law as ALT >3x ULN plus total bilirubin >2x ULN without cholestatic features, and the guidance notes that this pattern predicts a 10% or greater risk of fatal DILI in clinical trials. [16]

Dose Guidance and Practical Recommendations

Dose adjustment is the most actionable tool in managing this interaction.

Acetaminophen Dosing with MK-677

• Occasional use (fewer than 5 days/week): No dose adjustment required for acetaminophen at standard OTC doses (500 to 1,000 mg per dose, no more than 3,000 mg/day) in healthy adults with normal baseline LFTs.
• Regular use (5 or more days/week): Cap total daily acetaminophen at 2,000 mg/day and monitor LFTs every 8 to 12 weeks.
• Chronic pain requiring daily acetaminophen: Consider an alternative analgesic (e.g., topical diclofenac for localized pain, low-dose NSAIDs with gastroprotection if renal function permits) to reduce hepatic overlap. A 2018 Cochrane review found topical NSAIDs provided similar pain relief to oral NSAIDs for osteoarthritis with substantially lower systemic exposure. [17]

MK-677 Dosing Considerations

MK-677 is not FDA-approved. Research protocols have used 10 mg/day and 25 mg/day. [11, 12] The 10 mg/day dose produces approximately 60% of the IGF-1 elevation seen with 25 mg/day, based on dose-response data from early phase studies. [2] Patients who require regular acetaminophen may consider the 10 mg/day dose to minimize hepatic burden, though no head-to-head safety comparison in the context of acetaminophen co-use has been published.

N-Acetylcysteine (NAC) as a Buffer

NAC replenishes glutathione and is the standard antidote for acetaminophen overdose. [4] Some clinicians using MK-677 in research protocols co-prescribe oral NAC 600 mg once or twice daily as a preventive measure when acetaminophen use is unavoidable. This practice is not supported by a randomized trial in this specific combination, but the safety profile of NAC at 600 to 1,200 mg/day is well-established in the hepatology literature. [18] The rationale is pharmacologically sound even in the absence of direct trial data.

Patient Counseling Points

Patients combining MK-677 and acetaminophen should understand the following before they proceed.

MK-677 is not FDA-approved. Any use is off-label or within a research context, and the long-term safety profile in humans is incompletely characterized. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency notes that GH axis manipulation carries risks including glucose intolerance, fluid retention, and potential effects on neoplastic tissue, and that patients should be counseled accordingly. [19]

Read every OTC label. Acetaminophen is present in more than 600 products in the United States, including combination cold, flu, and sleep aids. [9] Patients who think they are taking 1,500 mg/day may actually be consuming 3,000 mg/day when hidden sources are counted. The FDA's 2014 consumer advisory specifically warns about this problem. [20]

Alcohol amplifies risk substantially. Even two to three drinks per day reliably increases NAPQI production and depletes glutathione. [14] Patients using MK-677 should be advised to keep alcohol consumption below 7 standard drinks per week and avoid alcohol entirely on days when acetaminophen is used.

Stop-and-call criteria matter. Patients should know to stop both agents and contact their provider if they develop jaundice, right upper quadrant pain lasting more than 24 hours, or persistently dark urine.

"Clinicians should advise patients that no over-the-counter pain reliever is entirely without risk, and that the safe dose of acetaminophen in any individual depends on their total hepatic burden from all sources," according to the American College of Gastroenterology's 2014 practice guidelines on DILI. [13]

How This Interaction Compares to Other MK-677 Drug Interactions

Acetaminophen is not the highest-priority interaction concern with MK-677. For context, the interactions below carry equal or greater clinical weight.

Insulin and Oral Antidiabetics

MK-677 raises fasting glucose by inducing insulin resistance at the level of skeletal muscle. The phase I/II trial data show mean fasting glucose increases of 0.3 to 0.5 mmol/L (5 to 9 mg/dL) at 25 mg/day. [15] Patients on sulfonylureas or insulin may need dose adjustments. This interaction is more immediately dangerous than the acetaminophen interaction for most patients.

CYP3A4 Inhibitors and Inducers

Strong CYP3A4 inhibitors (ketoconazole, ritonavir) can raise ibutamoren plasma concentrations significantly. [6] Strong inducers (rifampin, carbamazepine) can reduce ibutamoren exposure. Neither interaction has been studied in a dedicated DDI trial, but the pharmacokinetic logic follows directly from ibutamoren's metabolic pathway.

Corticosteroids

Corticosteroids blunt the GH response to secretagogues, reducing the clinical effect of MK-677. [19] Concurrent use may produce a pharmacodynamic antagonism that renders the ibutamoren ineffective at standard doses.

Other Hepatotoxins

Combining MK-677 with anabolic steroids, which have well-documented hepatotoxicity especially in oral 17-alpha-alkylated forms, represents a more serious hepatic risk than the acetaminophen interaction. [21] The acetaminophen interaction is clinically manageable through dose capping and monitoring. Oral anabolic steroid co-use is a more absolute concern.

Summary of the Evidence Gaps

The MK-677 and acetaminophen interaction has not been studied in a dedicated clinical trial. The assessment above is built from:

1. Pharmacokinetic data for each drug independently
2. Mechanistic reasoning about hepatic oxidative stress and glutathione metabolism
3. Clinical monitoring thresholds established for acetaminophen DILI
4. Phase II safety data for MK-677 at 10 to 25 mg/day in populations without liver disease

The absence of a direct interaction study means the severity rating of "moderate" is based on mechanistic plausibility, not observed clinical event rates. Clinicians and patients should weight this uncertainty appropriately. Given that MK-677 is not FDA-approved and is used primarily in research or off-label contexts, providers prescribing or supervising its use carry additional responsibility for active safety monitoring.

The American Association for the Study of Liver Diseases (AASLD) recommends that any patient using a compound with uncertain hepatic safety profile alongside known hepatotoxins should have LFTs checked at baseline and at 8-week intervals. [13] That recommendation applies directly to this combination.